PROFOUND MEDICAL CORP (PROF)
CA74319B5027 - Common Stock
We assign a fundamental rating of 3 out of 10 to PROF. PROF was compared to 192 industry peers in the Health Care Equipment & Supplies industry. While PROF seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PROF is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PROF had negative earnings in the past year.
In the past year PROF has reported a negative cash flow from operations.
In the past 5 years PROF always reported negative net income.
PROF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PROF (-65.06%) is worse than 77.60% of its industry peers.
The Return On Equity of PROF (-91.63%) is worse than 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.06% | ||
| ROE | -91.63% | ||
| ROIC | N/A |
ROA(3y)-48.31%
ROA(5y)-43.24%
ROE(3y)-61.61%
ROE(5y)-62.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 60.87%, PROF perfoms like the industry average, outperforming 58.85% of the companies in the same industry.
In the last couple of years the Gross Margin of PROF has grown nicely.
The Profit Margin and Operating Margin are not available for PROF so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.59%
GM growth 5Y13.84%
2. Health
2.1 Basic Checks
PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PROF has more shares outstanding
Compared to 5 years ago, PROF has more shares outstanding
Compared to 1 year ago, PROF has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.60, we must say that PROF is in the distress zone and has some risk of bankruptcy.
PROF has a Altman-Z score of 0.60. This is comparable to the rest of the industry: PROF outperforms 47.92% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that PROF is not too dependend on debt financing.
PROF has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.6 |
ROIC/WACCN/A
WACC8.92%
2.3 Liquidity
PROF has a Current Ratio of 6.58. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
PROF has a better Current ratio (6.58) than 81.77% of its industry peers.
A Quick Ratio of 5.48 indicates that PROF has no problem at all paying its short term obligations.
PROF's Quick ratio of 5.48 is fine compared to the rest of the industry. PROF outperforms 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.58 | ||
| Quick Ratio | 5.48 |
3. Growth
3.1 Past
PROF shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.17%.
PROF shows a small growth in Revenue. In the last year, the Revenue has grown by 7.75%.
Measured over the past years, PROF shows a very strong growth in Revenue. The Revenue has been growing by 29.07% on average per year.
EPS 1Y (TTM)2.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q8.7%
Revenue 1Y (TTM)7.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y29.07%
Revenue growth Q2Q59.82%
3.2 Future
Based on estimates for the next years, PROF will show a very strong growth in Earnings Per Share. The EPS will grow by 23.78% on average per year.
PROF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.84% yearly.
EPS Next Y21.67%
EPS Next 2Y28.03%
EPS Next 3Y19.71%
EPS Next 5Y23.78%
Revenue Next Year69.78%
Revenue Next 2Y118.98%
Revenue Next 3Y89.71%
Revenue Next 5Y73.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PROF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PROF's earnings are expected to grow with 19.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.03%
EPS Next 3Y19.71%
5. Dividend
5.1 Amount
No dividends for PROF!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROFOUND MEDICAL CORP
NASDAQ:PROF (5/1/2024, 12:59:03 PM)
7.46
+0.02 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap182.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.06% | ||
| ROE | -91.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.58 | ||
| Quick Ratio | 5.48 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y